[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Washington University School of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":622},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,247,0,25,[9,44,71,96,116,132,153,174,196,224,254,284,307,336,363,381,405,428,450,471,498,520,548,574,597],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100053346",false,"NCT05991440","Examining Racial and Socioeconomic Differences in Chronic Low Back Pain","Racial and Socioeconomic Differences in Chronic Low Back Pain","ERASED","Inclusion:\n\n* Non-specific cLBP that has persisted for at least 3 months and has resulted in pain on at least half the days in the past 6 months.\n* Age 18 - 85; the lower end of this age range was chosen to capture the growing prevalence of young adults with cLBP, and participants over 85 years are increasingly likely to meet one or more exclusion criteria.\n* Participants report ethnic group as non-Hispanic and racial group as either Black\u002FAfrican American or White\u002FCaucasian.\n\nExclusion:\n\n* Low back pain that is attributable to other factors such as ankylosing spondylitis, infection, malignancy, compression fracture of other trauma.\n* Systemic rheumatic disease\u002Fcondition (e.g. rheumatoid arthritis, systemic lupus erythematosus, fibromyalgia).\n* Any other chronic pain condition that the participant believes to be more prominent or severe than the low back pain.\n* A history of clinically significant surgery to the low back within the past year.\n* Uncontrolled hypertension (i.e. SBP\u002FDBP of \\> 150\u002F95), cardiovascular or peripheral arterial disease.\n* Poorly controlled diabetes (HbA1c \\> 8%).\n* Neurological disease (e.g. Parkinson's, multiple sclerosis, epilepsy).\n* Serious psychiatric disorder requiring hospitalization within the past 12 months or characterized by active suicidal ideation.\n* Diminished cognitive function that would interfere with understanding of study procedures.","ALL","18 Years","85 Years",{"count":21,"type":22},240,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to gain a better understanding of how people's racial background and socioeconomic status (e.g., income, education, and employment) impact their experiences of chronic low back pain (cLBP).",[26],"Chronic Pain",[28,29,30],"lower back pain","Race","Socioeconomic","RECRUITING","2026-07-10",{"date":34,"type":35},"2026-07-13","ACTUAL",{"date":37,"type":35},"2024-04-22",{"date":39,"type":22},"2028-12-31",{"name":41,"class":42},"Washington University School of Medicine","OTHER",1,{"id":45,"slug":4,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":43},"100054009","NCT06785129","Endometriosis and Migraine","Mechanisms Underlying Endometriosis and Migraine Comorbidity","EMC","Inclusion Criteria:\n\n1. Patients with diagnosed endometriosis, migraine, or both endometriosis and migraine\n2. Healthy control subjects with no history of chronic pain\n3. Age 12-45\n4. Assigned female sex at birth\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. Presence of prolactinoma\n3. Presence of psychiatric, neurological, endocrinological and\u002For developmental conditions and taking medications for these conditions\n4. Current use of dopamine agonist or SSRI medications\n5. For patients aged 12-17 not having a parent\u002Flegal guardian willing to sign the consent and answer surveys about their child's health",true,"FEMALE","12 Years","45 Years",{"count":56,"type":22},120,"This study aims to determine differences in experimental pain and sex hormone levels between patients with migraine, patients with endometriosis, patients with migraine and endometriosis, and healthy controls. Participants will complete surveys, experimental pain paradigms and collection of samples for hormone analyses.",[59,60],"Migraine","Endometriosis",[59,62,63,64],"endometriosis","hormones","pain",{"date":34,"type":35},{"date":67,"type":35},"2025-02-12",{"date":69,"type":22},"2030-01-01",{"name":41,"class":42},{"id":72,"slug":4,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":89,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100053743","NCT00869817","Dominantly Inherited Alzheimer Network (DIAN)","DIAN","Inclusion Criteria:\n\n* Written informed consent obtained from participant and collateral source prior to any study-related procedures.\n* Aged 18 (inclusive) or older and the child of an affected individual (clinically or by testing) in a pedigree with a known mutation for ADAD.\n* Cognitively normal to very mild or mild cognitive impairment (CDR score range 0-1.0). Primary enrollment will focus on the recruitment of asymptomatic adult children who are more than 15 years younger than the estimated age of symptom onset. Enrollment of new participants with moderate cognitive impairment is allowed with the prior approval of the DIAN Coordinating Center.\n* Has two persons who are not their full-blooded siblings who can serve as collateral sources for the study.\n* Fluent in a language approved by the DIAN Coordinating Center at about the 6th grade level (international equivalent) or above.\n\nExclusion Criteria:\n\n* Under age 18\n* Medical or psychiatric illness that would interfere in completing initial and follow-up visits\n* Requires nursing home level care\n* Has no one who can serve as a study informant",{"count":78,"type":22},700,"The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.",[81],"Alzheimer's Disease",[83,84,85,86,87,88],"Alzheimer's disease","antecedent biomarkers","Amyloid Precursor Protein (APP) mutation","presenilin I (PS1) mutation","presenilin 2 (PS2) mutation","Autosomal Dominant Alzheimer's Disease",{"date":34,"type":35},{"date":91,"type":4},"2009-01",{"date":93,"type":22},"2027-07",{"name":41,"class":42},26,{"id":97,"slug":4,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":51,"sex":17,"minAge":101,"maxAge":102,"enrollmentInfo":103,"targetDuration":4,"studyType":105,"phases":106,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":110,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":43},"100053991","NCT05654012","Migraine in Adolescents","Inclusion criteria for healthy participants:\n\n1. Age 10-13\n2. Males or females (biological sex)\n3. Not diagnosed with migraine or having migraine symptoms\n4. With a first degree relative diagnosed with migraine (for the Fam-His group) or without a first or a second degree relative diagnosed with migraine (for the No-Fam-His group)\n\nInclusion criteria for participants with migraine:\n\n1. Age 10-13\n2. Males or females (biological sex)\n3. Diagnosed with migraine or having migraine symptoms\n4. Migraine duration \\> 6 months\n5. Without preventative treatment or with stable preventative treatment for migraine (no change in intervention in the last 6 months)\n\nExclusion Criteria for the healthy group:\n\n* Participants will not be enrolled if any of the following criteria exist and based on the investigator discretion:\n\n  1. Diagnosis of any chronic pain syndrome\n  2. Diagnosis of a neurological, developmental, pubertal, or psychiatric disorder\n  3. Taking pain or psychiatric medications regularly\n  4. Having an MRI contraindication such as metal in the body or claustrophobia\n  5. Not able to understand and communicate in English\n\n     Exclusion Criteria for the migraine group\n* Participants will not be enrolled if any of the following criteria exist and based on the investigator discretion:\n\n  1. Diagnosis of any chronic pain syndrome other than migraine\n  2. Diagnosis of a neurological, developmental, pubertal, or psychiatric disorder\n  3. Having an MRI contraindication such as metal in the body or claustrophobia\n  4. Not able to understand and communicate in English","10 Years","13 Years",{"count":104,"type":22},250,"INTERVENTIONAL",[107],"NA","Aim 1. To identify psychophysical and neural factors predicting migraine onset in adolescents\n\nAim 2a. To determine hormonal, psychophysical, and neural changes associated with migraine onset.\n\nAim 2b. To identify the temporal relationships between hormonal, psychophysical, and neural changes preceding vs. following migraine onset.\n\nAim 3. To identify psychophysical and neural factors predicting migraine prognosis in adolescents with migraine.",[59],{"date":34,"type":35},{"date":112,"type":35},"2023-06-01",{"date":114,"type":22},"2030-03-15",{"name":41,"class":42},{"id":117,"slug":4,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":4,"eligibilityCriteria":121,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":122,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":43},"100053243","NCT06101303","Endometriosis Pain","The Mechanisms Underlying Endometriosis Pain","Inclusion criteria:\n\n* Patients with pelvic pain with and without endometriosis scheduled for an operative laparoscopic surgery for endometriosis diagnosis and\u002For treatment\n* Age 12-45\n* Females\n\nExclusion criteria:\n\n* Pregnancy\n* Planned hysterectomy or oophorectomy\n* Co-occurring vaginismus and\u002For vulvodynia\n* For patients aged 12-17 not having a parent\u002Flegal guardian willing to sign the consent and answer surveys about their child's health",{"count":56,"type":22},"Aim 1. To determine the factors contributing to pain in patients with chronic pelvic pain with and without endometriosis Aim 2. To determine the changes following endometriosis lesion removal surgery in pain and sex hormone levels.\n\nAim 3. To identify factors predicting clinical pain reduction after lesion removal surgery.\n\nAdditional exploratory aims might compare subgroups of patients such as patients with vs. without endometriosis, with vs. without additional chronic pain syndromes, and with vs. without hormonal treatment. In addition, the role of lesion-specific immune signatures and psychological factors on pain will be explored.\n\nPatients with pelvic pain potentially due to endometriosis will complete questionnaires including social, health, behavioral, and psychological questionnaires. Patients will also complete a 2.5 hours study visit of psychophysical assessments of thermal and pressure stimuli. In addition, blood, urine, and saliva samples will be collected for hormonal, immune, and genetic analyses. Additional samples might be collected and stored for future analyses. For some participants, these procedures will be completed several times, including before the surgery as well as 3 months, 6 months and 1 year after surgery. After the surgery, surveys assessing pain and other symptoms will be sent every week on the first month and then monthly for 1 year. In addition, during the surgery, biopsies will be collected and analyzed to determine hormonal, immune and genetic factors.\n\nFor adolescents, a parent\u002Flegal guardian will be asked to assist in completing some of the health-related surveys (i.e., physical developmental survey, health survey, migraine history survey).",[125,60],"Pelvic Pain",{"date":34,"type":35},{"date":128,"type":35},"2023-09-29",{"date":130,"type":22},"2029-09-01",{"name":41,"class":42},{"id":133,"slug":4,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":52,"minAge":139,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":43},"100053994","NCT06023225","Sex Hormones, Postoperative Pain and Opioid Use","Relationship Between Sex Hormones, Postoperative Pain and Opioid Use: the Role of Immune Factors","SPO","Inclusion Criteria:\n\nPediatric female patients between the ages 11-16 undergoing an orthopedic (trauma and non-trauma) surgical procedure involving a long bone or joint, or the spine, English speaking\n\nExclusion Criteria:\n\nPregnancy; Diagnosis of chronic pain, Psychiatric, developmental or neurological disorders, Disorders that are associated with pubertal maturation (e.g., precocious puberty).","11 Years","16 Years",{"count":142,"type":22},210,"Aim 1- To identify relationships between sex hormone levels and postoperative pain and opioid use.\n\nAim 2: To determine whether the effects of testosterone on postoperative pain and opioid use are mediated by immune factors",[145,146],"Postoperative Pain","Opioid Use",{"date":34,"type":35},{"date":149,"type":35},"2023-09-01",{"date":151,"type":22},"2029-07-01",{"name":41,"class":42},{"id":154,"slug":4,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":51,"sex":17,"minAge":158,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":43},"100053824","NCT02604563","Aging, Geriatric Syndromes and Clonal Hematopoiesis","Inclusion Criteria:\n\n* At least 50 years of age.\n* Able to understand written and spoken English.\n* Able to understand and willing to sign an IRB-approved written informed consent document (or that of a legally authorized representative, if applicable for the trauma cohort)\n\nExclusion Criteria:\n\n* Inability or unwillingness to complete health questionnaire (with the exception of hip and knee replacement participants).\n* History of a recent (\\\u003C30 days) acute viral illness.\n* Current cancer diagnosis and currently receiving chemotherapy or undergoing radiation therapy. A prior history of cancer is allowed if the participant completed therapy \\> 1 year prior to enrollment; participants with a prior diagnosis of cancer will be asked to sign a release of information for the research team to obtain records regarding their prior cancer treatment.\n* Current use of drugs that cause DNA damage (e.g. Cytoxan, azathioprine, etc.) for the treatment of a non-malignant disease.\n* Vulnerable populations (e.g. prisoners).\n* Known infection with Hepatitis B or C, HTLV, or HIV.\n* Additional exclusion for optional bone marrow aspirate\u002Fbiopsy substudy:\n\n  * Use of medications for anticoagulation or \"blood thinning\" including warfarin, low molecular weight heparins (enoxaparin, daltaparin) or direct-acting oral anticoagulants (dabigatran, rivaroxaban, apixaban, edoxaban or betrixaban)\n  * allergy to lidocaine or other local anesthetics.","50 Years",{"count":160,"type":22},2000,"In this study the investigators will incorporate a wide range of clinical variables associated with aging and cardiovascular disease to determine whether they are associated with mutation status independent of chronologic age. Clinically, aging can be operationalized using geriatric assessment, which entails a comprehensive multi-dimensional assessment of the health of an older adult, including measures of comorbidity, polypharmacy, functional status, cognition, depression, falls, social activities and social support. Given that aging is heterogeneous, geriatric assessment allows greater specificity for aging than chronological age alone.",[163,164,165,166],"Geriatrics","Aged","Geriatric Syndromes","Cardiovascular Diseases","2026-07-09",{"date":34,"type":35},{"date":170,"type":35},"2016-03-10",{"date":172,"type":22},"2030-04-30",{"name":41,"class":42},{"id":175,"slug":4,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":177,"acronym":178,"eligibilityCriteria":179,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":105,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":43},"100053947","NCT06605196","Improving Cancer Prevention and Control Through Academic-local Public Health Department Partnerships","AHD","Inclusion Criteria:\n\n* Local health department practitioners who are involved in the implementation of cancer prevention and control programs within their communities and are engaged in an academic-health department partnership.\n* Employees in academic settings currently partnering with local health departments. These partnerships could be located anywhere within the United States.\n\nExclusion Criteria:\n\n• Individuals under the age of 18 years old.",{"count":181,"type":22},364,[107],"The purpose of this study is to understand how to leverage structures and processes of academic health department (AHD) partnerships to facilitate implementation of cancer related evidence-based programs and policies (EBPPs).",[185],"Cancer",[187,188],"Improving cancer prevention and control","academic-local public health department partnerships","NOT_YET_RECRUITING",{"date":34,"type":35},{"date":192,"type":22},"2026-09-30",{"date":194,"type":22},"2028-11-30",{"name":41,"class":42},{"id":197,"slug":4,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":105,"phases":204,"briefSummary":207,"conditions":208,"keywords":211,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":43},"100620252","NCT07355205","First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","A Phase Ib\u002FII, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)","FLINN","Inclusion Criteria:\n\n* Histologically or cytologically confirmed, previously untreated or recurrent metastatic NSCLC.\n* Availability of archival biopsy tissue or willingness to undergo a biopsy prior to C1D1 for biomarker analysis, including PD-L1 by IHC using a CLIA-certified test. Results of the PD-L1 testing are not required for enrollment.\n* Measurable disease per RECIST 1.1.\n* At least 18 years of age.\n* ECOG performance status ≤ 1\n* Adequate organ and marrow function, as defined below:\n\n  * Absolute neutrophil count ≥ 1.5 K\u002Fcumm\n  * Platelets ≥ 100 K\u002Fcumm\n  * Hemoglobin ≥ 9.0 g\u002FdL\n  * AST(SGOT)\u002FALT(SGPT) ≤ 2.5 x IULN without hepatic metastasis and ≤ 5 x IULN with hepatic metastasis\n  * Total bilirubin ≤ 2 x IULN (except participants with Gilbert's syndrome who must have total bilirubin \\\u003C 3.0 mg\u002FdL)\n  * Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault\n  * INR ≤ 1.5 unless using therapeutic anticoagulation\n  * PTT\u002FaPTT \\\u003C 1.5 x IULN unless using therapeutic anticoagulation\n* Patients with brain metastases are eligible if they have previously treated with surgery or radiation therapy, are neurologically stable after a washout period of at least 2 weeks, and are not receiving corticosteroids at dose higher than 10 mg of prednisone or equivalent on C1D1.\n* The effects of the treatment regimen on the developing human fetus are unknown. For this reason, people of childbearing potential and people able to father a child must agree to use highly effective methods of contraception, according to the protocol, from the time of consent through 6 months after the last dose of study treatment.\n* Ability to understand and willingness to sign an IRB-approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Mixed histology including small cell lung cancer.\n* Tumor harboring any of the following:\n\n  * classic EGFR mutations\n  * HER2 mutation\n  * ALK fusion\n  * ROS1 fusion\n  * RET fusion\n  * NTRK fusion\n  * MET Exon14 skipping mutation\n  * BRAF V600E mutation\n* Use of any live vaccines within 28 days of C1D1.\n* Prior chemotherapy in the adjuvant setting or during concurrent radiation therapy for locally advanced disease within 12 months prior to enrollment. If the interval from the last treatment is 12 months or longer, the patient is eligible.\n* Radiation therapy within 14 days prior to C1D1.\n* History of major surgery within 14 days prior to C1D1.\n* Underlying medical conditions that, in the Investigator's opinion, will make the administration of study treatment hazardous, including but not limited to:\n\n  * History of interstitial lung disease or noninfectious pneumonitis,\n  * Active viral, bacterial or fungal infections requiring parenteral treatment within 14 days of C1D1,\n  * Clinically significant cardiovascular disease,\n  * A condition that may obscure the interpretation of toxicity determination or AEs,\n  * History of prior solid-organ transplantation.\n* Concurrent medical condition requiring the use of supra-physiologic doses of corticosteroids (\\> 10 mg\u002Fday of oral prednisone or equivalent) or immunosuppressive medications (absorbable topical corticosteroids are not excluded).\n* HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.\n* Evidence of chronic hepatitis B (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection.\n* History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection.\n* Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n* Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma\u002Fatopy.\n\n  * Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.\n  * Participants with asthma who require intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections will not be excluded from this study.\n  * Participants on chronic systemic corticosteroids will be excluded from the study.\n* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.\n* Use of other investigational drugs (drugs not marketed for any indication) within 28 days or 5 half-lives (whichever is longer) of C1D1.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to any agents used in the study, or known hypersensitivity to recombinant proteins, or any excipient contained in the trial formulations.\n* Pregnant and\u002For breastfeeding. People of childbearing potential must have a negative pregnancy test within 7 days of study entry.",{"count":95,"type":22},[205,206],"PHASE1","PHASE2","This is a single center, phase Ib\u002FII study combining an anti-PD-1 antibody and an anti-CTLA-4 antibody with IL-15. It is testing the hypothesis that the addition of nogapendekin alfa inbakicept to nivolumab and ipilimumab will augment the clinical activity of those two drugs.",[209,210],"Non-small Cell Lung Cancer Stage IV","Non-small Cell Lung Cancer Recurrent",[212,213,214,215],"Non-small cell lung cancer","Stage IV","Immunotherapy","IL-15 super agnoist","2026-06-30",{"date":218,"type":35},"2026-07-02",{"date":220,"type":22},"2026-07-31",{"date":222,"type":22},"2032-07-31",{"name":41,"class":42},{"id":225,"slug":4,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":230,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":105,"phases":233,"briefSummary":234,"conditions":235,"keywords":241,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":251,"leadSponsor":253,"locationsCount":43},"100640146","NCT07593079","Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer","Optimizing PSMA Imaging for Enhanced Detection of Residual and Metastatic Prostate Cancer in Low PSA Recurrence (OPERA) Study","Inclusion Criteria:\n\n* Histologically or cytologically confirmed biochemically recurrent prostate cancer, with original diagnosis no more than 2 years from date of consent.\n* Intermediate unfavorable or high-risk prostate cancer.\n* All patients under consideration for radiation therapy, either at the time of first recurrence or in salvage radiation therapy will be included.\n* Patients who have started bicalutamide up to a maximum of 3 days prior to randomization will be allowed to be on protocol. Otherwise, a washout period of at least 42 days will be required.\n* Biological males, at least 18 years of age.\n* Prostate specific antigen (PSA) \\\u003C 1.0 ng\u002FmL.\n* Agreement to adhere to Lifestyle Considerations throughout study duration\n* Ability to understand and willingness to sign an IRB approved written informed consent document.\n\nExclusion Criteria:\n\n* Patients currently on androgen deprivation therapy (ADTs).\n* Currently receiving any other investigational agents.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to POSLUMA, furosemide, bicalutamide, or other agents used in the study.","MALE",{"count":232,"type":22},20,[206],"This is a randomized, open-label, pilot study assessing the impact of a short course of bicalutamide on PSMA expression in patients with prostate cancer belonging to the intermediate unfavorable or high risk group, who have low levels of PSA. Adult patients with biochemically recurrent prostate cancer (BCR PCa) who have a PSA of less than 1.0 ng\u002FmL and who have undergone complete prostatectomy and\u002For will be undergoing radiotherapy, in combination with standard of care bicalutamide, will be recruited to this study. Patients will be randomized in a 1:1 ratio into Group A (baseline PSMA PET\u002FCT only with bicalutamide standard of care) or Group B (baseline PSMA PET\u002FCT and an additional PSMA PET\u002FCT after 2 weeks of bicalutamide).",[236,237,238,239,240],"Prostate Cancer","Recurrent Prostate Cancer","Metastatic Prostate Cancer","Prostate Cancer Recurrent","Prostate Cancer Metastatic",[242,243,244,245,246],"Prostate cancer","Low PSA","PSMA PET","BCR","Bicalutamide","2026-06-29",{"date":249,"type":35},"2026-07-01",{"date":220,"type":22},{"date":252,"type":22},"2027-10-31",{"name":41,"class":42},{"id":255,"slug":4,"hasResults":11,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":105,"phases":263,"briefSummary":265,"conditions":266,"keywords":268,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":43},"100596000","NCT07039760","Asciminib With or Without Sildenafil for Brain Tumors","An Early Phase 1 Study of Asciminib With or Without Sildenafil for Brain Tumors","Inclusion Criteria:\n\n* Ages 18-39 years old, inclusive.\n* Radiographic evidence of a recurrent\u002Fprogressive brain tumor.\n* Tumor must be predominantly in an intraparenchymal location.\n* Deemed operable (able to be resected or have an open or stereotactic needle biopsy) by treating neurosurgeon.\n* ECOG Performance Status of ≥ 2. Patients who are unable to walk because of paralysis but who are up in a wheelchair will be considered ambulatory for the purposes of the performance score.\n* Bone Marrow:\n\n  * ANC (Absolute neutrophil count) ≥ 1000\u002Fµl (unsupported).\n  * Platelets ≥ 100,000\u002Fµl (may be supported by transfusion).\n  * Hemoglobin \\> 8 g\u002FdL (may be supported by transfusion).\n* Renal:\n\n  * Serum creatinine ≤ upper limit of institutional normal.\n* Hepatic:\n\n  * Bilirubin ≤ 1.5 times upper limit of normal for age.\n  * ALT (SGPT) ≤ 3 times institutional upper limit of normal for age.\n  * AST (SGOT) ≤ 3 times institutional upper limit of normal for age.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants. All patients and\u002For their parents or legal guardians must sign an IRB approved written informed consent document.\n\nExclusion Criteria:\n\n* Tumors suspected to be pituitary tumors or tumors of the meninges.\n* Tumors that are suspected of a non-CNS primary location or history of non-CNS malignancy).\n* Unable to take tablets orally\n* Pregnant and\u002For breastfeeding. Subjects of childbearing potential must have a negative serum or urine pregnancy test within 10 days prior to Day 1.\n* Active infection requiring treatment or an unexplained febrile (\\> 101.5o F) illness.\n* Known immunosuppressive disease or human immunodeficiency virus infection.\n* Any active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or pulmonary disease.\n* Any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).\n* Inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.","39 Years",{"count":262,"type":22},12,[264],"EARLY_PHASE1","Dissemination of medulloblastoma is an independent risk factor of poor prognosis. Dissemination of medulloblastoma at recurrence is nearly universally fatal. ABL1 and 2 have been recently found to mediate the dissemination of medulloblastoma. Genetically inactivating ABL1 and 2 resulted in decreased leptomeningeal medulloblastoma and improved overall survival (OS) in rodent models. ABL kinases have also been shown to play a role in the malignant properties of glioblastoma. Asciminib is an FDA approved for the treatment of chronic myeloid leukemia and is well tolerated, likely due to its specificity for ABL1 and ABL2. Asciminib is a P-glycoprotein (P-gp) substrate and thus may be susceptible to being pumped out of tumor cells and brain endothelial cells. It is unclear if asciminib can enter the central nervous system (CNS) and brain tumors in adequate concentration to have anti-tumor effects.",[267],"Brain Tumor",[269,270,271,272,273,274,275,276,277],"Asciminib","Sildenafil","ABL1","ABL2","Tyrosine kinase inhibitor","Pediatric brain tumor","Brain tumor","Pharmacokinetics","Pharmacodynamics",{"date":249,"type":35},{"date":280,"type":22},"2026-08-31",{"date":282,"type":22},"2028-03-31",{"name":41,"class":42},{"id":285,"slug":4,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":105,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":43},"100590559","NCT06968988","Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma","Phase I Study With Expansion Cohort of Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma","Inclusion Criteria:\n\n* Histologically or cytologically confirmed soft tissue sarcoma that is metastatic or unresectable.\n* Must have received at least one but no more than 3 lines of therapy in the metastatic setting, with progression on last line of therapy. Neoadjuvant or adjuvant therapy completed more than one year prior does not count towards as a line of therapy in the metastatic. Individuals with alveolar soft part sarcoma may enroll without being refractory to at least one line of therapy.\n* Measurable disease per RECIST 1.1.\n* At least 18 years of age.\n* ECOG performance status ≤ 1.\n* Adequate bone marrow and organ function as defined below:\n\n  * Absolute neutrophil count (ANC) ≥ 1.5 K\u002Fcumm without granulocyte colony-stimulating factor support within 2 weeks prior to screening laboratory collection\n  * Platelets ≥ 100 K\u002Fcumm without transfusion within 2 weeks prior to screening laboratory collection\n  * Hemoglobin ≥ 9.0 g\u002FdL without transfusion within 2 weeks prior to screening laboratory collection\n  * INR ≤ 1.5 and aPTT ≤ 1.2 x IULN. For subjects on Factor Xa inhibitors, criteria does not apply.\n  * Total bilirubin ≤ 1.5 x IULN (for subjects with Gilbert's disease ≤ 3 x IULN)\n  * AST(SGOT), ALT(SGPT), and alkaline phosphatase (ALP) ≤ 3.0 x IULN. For subjects with documented bone metastasis, ALP ≤ 5.0 x IULN.\n  * Serum albumin ≥ 2.8 g\u002FdL.\n  * Calculated creatinine clearance ≥ 40 mL\u002Fmin by Cockcroft-Gault.\n  * UPCR ≤ 1 mg\u002Fmg (≤ 113.2 mg\u002Fmmol) creatinine.\n* Recovery to baseline or ≤ grade 1 from AEs, including immune-related AEs related to any prior treatments, unless AEs are clinically nonsignificant and\u002For stable on supportive therapy (e.g., physiological replacement of corticosteroid). Low-grade or controlled toxicities such as alopecia, ≤ grade 2 hypomagnesemia, ≤ grade 2 neuropathy are permitted.\n* Sexually active fertile subjects and their partners must agree to use highly effective method of contraception during the course of the study and for the following durations after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (eg, condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods:\n\n  * 186 days after last dose of zanzalintinib (for women) or 96 days after last dose of zanzalintinib (for men).\n  * 5 months after the last dose of nivolumab or 3 months after the last dose of ipilimumab.\n* Female subjects of childbearing potential must not be pregnant at screening. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \\\u003C 55 years-of-age must have a serum follicle stimulating hormone \\[FSH\\] level \\> 40 mIU\u002FmL to confirm menopause). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Translocation-driven sarcoma except for ASPS.\n* Prior treatment with zanzalintinib, cabozantinib, PD-1 inhibitor (eg, cemiplimab, nivolumab, pembrolizumab), PD-L1 inhibitor (eg, atezolizumab, avelumab, durvalumab), or CTLA-4 inhibitor (eg, ipilimumab).\n* Receipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitor) within 2 weeks before first dose of study treatment.\n* Receipt of any type of cytotoxic, biologic, or other systemic anticancer therapy (including investigational) within 4 weeks before first dose of study treatment.\n* Radiation therapy for bone metastasis within 2 weeks before first dose of study treatment; any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before first dose of study treatment. Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible.\n* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and\u002For surgery (including radiosurgery) and stable for at least 4 weeks before first dose of study treatment. Note: Eligible subjects must be neurologically asymptomatic and without corticosteroid treatment at the time of enrollment. Note: Base of skull lesions without definitive evidence of dural or brain parenchymal involvement are allowed.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to zanzalintinib, ipilimumab, nivolumab, or other agents used in the study.\n* Concomitant anticoagulation with warfarin or other vitamin-K antagonists, direct thrombin inhibitors, or antiplatelet agents (e.g. clopidogrel). Allowed anticoagulants are the following:\n\n  * Prophylactic use of low-dose aspirin for cardio-protection (per local applicable guidelines) and low-dose low molecular weight heparins (LMWH).\n  * Therapeutic doses of LMWH or anticoagulation with direct factor Xa inhibitors rivaroxaban, edoxaban, or apixaban in subjects without known brain metastases who are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen. Note: subjects must have discontinued oral anticoagulants within 3 days or 5 half-lives prior to first dose of study treatment, whichever is longer.\n* Any complementary medications (e.g. herbal supplements or traditional Chinese medicines) to treat the disease under study within 2 weeks before first dose of study treatment.\n* Uncontrolled, significant intercurrent or recent illness including, but not limited to:\n\n  * Unstable or deteriorating cardiovascular disorders:\n\n    * Congestive heart failure NYHA Class 3 or 4, or Class 2 or higher unstable angina pectoris, new-onset angina, serious cardiac arrhythmias (e.g. ventricular flutter, ventricular fibrillation, Torsades de pointes).\n    * Uncontrolled hypertension defined as sustained blood pressure \\> 140 mmHg systolic or \\> 90 mmHg diastolic despite optimal antihypertensive treatment.\n    * Stroke (including transient ischemic attack), myocardial infarction, or other clinically significant arterial thrombotic and\u002For ischemic event within 6 months before first dose of study treatment.\n    * Pulmonary embolism or deep vein thrombosis or prior clinically significant venous events within 3 months before first dose of study treatment. Note: Subjects with a diagnosis of DVT within 6 months are allowed if asymptomatic and stable at screening and are on a stable dose of the anticoagulant for at least 1 week before first dose of study treatment without clinically significant hemorrhagic complications from the anticoagulation regimen. Note: Subjects who don't require prior anticoagulation therapy may be eligible but must be discussed and approved by the PI.\n    * Prior history of myocarditis.\n  * Gastrointestinal disorders, including those associated with a high risk of perforation or fistula formation:\n\n    * Tumors invading the GI tract from external viscera\n    * Active peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis\n    * Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months before first dose unless cause of obstruction is definitively managed and subject is asymptomatic.\n    * Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose. Note: complete healing of an intra-abdominal abscess must be confirmed before first dose of study treatment.\n    * Known gastric or esophageal varices.\n    * Ascites, pleural effusion, or pericardial fluid requiring drainage in last 4 weeks.\n* Clinically significant hematuria, hematemesis, or hemoptysis of \\> 0.5 teaspoon (2.5 mL) of red blood, or other history of significant bleeding (e.g. pulmonary hemorrhage) within 12 weeks before first dose of study treatment.\n* Symptomatic cavitating pulmonary lesion(s) or endobronchial disease (asymptomatic or radiated lesions allowed).\n* Lesions invading major blood vessel including, but not limited to, inferior vena cava, pulmonary artery, or aorta. Note: subjects with intravascular tumor extension (e.g. tumor thrombus in renal vein on inferior vena cava) may be eligible following PI approval.\n* Other clinically significant disorders that would preclude safe study participation, in the opinion of the investigator. Specific conditions are noted below:\n\n  * Active infection requiring systemic treatment. Note: prophylactic antimicrobial treatments (antibiotics, antimycotics, antivirals) are allowed.\n  * Known infection with acute or chronic hepatitis B or C, known HIV or AIDS-related illness except for subjects meeting all of the following criteria:\n\n    * On stable anti-retroviral therapy\n    * CD4+ T cell count ≥ 200\u002FμL\n    * Undetectable viral load. Note: HIV testing will be performed at screening if and as required by local regulation. Note: to be eligible, participants taking CYP inhibitors (e.g. zidovudine, ritonavir, cobicistat, didanosine) orCYP3 inducers (efavirenz) must change to a different regimen not including these drugs 7 days prior to initiation of study treatment. Anti-retroviral therapies must have been received for at least 4 weeks prior to the first dose. Note: CD4+ T cell counts and viral load are monitored per standard of care by the local health provider.\n  * Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.\n  * Malabsorption syndrome.\n  * Pharmacologically uncompensated, symptomatic hypothyroidism.\n  * Moderate to severe hepatic impairment (Child-Pugh B or C).\n  * Requirement for hemodialysis or peritoneal dialysis.\n  * History of solid organ or allogeneic stem cell transplant.\n* Major surgery (e.g. GI surgery, removal or biopsy of brain metastasis) within 8 weeks prior to first dose of study treatment. Prior laparoscopic surgeries (e.g. nephrectomy) within 4 weeks prior to first dose of study treatment. Minor surgery (e.g. simple excision, tooth extraction) within 5 days before first dose of study treatment. Complete wound healing from major or minor surgery must have occurred at least prior to first dose of study treatment. Note: fresh tumor biopsies should be performed at least 5 days before the first dose of study treatment. Subjects with clinically relevant ongoing complications from prior surgical procedures, including biopsies, are not eligible.\n* Corrected QT interval calculated by the Fridericia formula (QTcF) \\> 480 ms within 14 days per ECG before first dose of study treatment. Note: triplicate ECG evaluations will be performed and the average of these 3 consecutive results for QTcF will be used to determine eligibility.\n* History of psychiatric illness likely to interfere with ability to comply with protocol requirements or give informed consent.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 14 days of study entry.\n* Inability to swallow tablets or ingest a suspension either orally or by a NG or PEG tube.\n* Another malignancy that requires active therapy and in the opinion of the Investigator would interfere with monitoring of radiologic assessments of response to study treatment, within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy\n* Any active, known, or suspected autoimmune disease. Note: subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger, or permitted to enroll.\n* Known positive test for tuberculosis infection if supported by clinical or radiographic evidence of disease.\n* History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), drug induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computerized tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.\n* Free thyroxine (FT4) outside the laboratory normal reference range. Asymptomatic subjects with FT4 abnormalities can be eligible after Principal Investigator approval.\n* Diagnosis of immunodeficiency or is receiving systemic steroid therapy (\\> 10 mg daily prednisone equivalent) or any other form of immunosuppressive therapy within 2 weeks prior to first dose of study treatment. Inhaled, intranasal, intraarticular, and topical corticosteroids and mineralocorticoids are allowed. Note: Adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease. Transient short-term use of higher doses of systemic corticosteroids for allergic conditions (eg, contrast allergy) is also allowed.\n* Administration of a live, attenuated vaccine within 30 days before first dose of study treatment.",{"count":291,"type":22},18,[205],"The investigators hypothesize that zanzalintinib in combination with ipilimumab and nivolumab will be well tolerated and serve as a potential therapeutic strategy in metastatic soft tissue sarcoma (mSTS) including myxofibrosarcoma, undifferentiated pleomorphic sarcoma, dedifferentiated liposarcoma, cutaneous angiosarcoma, and undifferentiated sarcoma histologies.",[295],"Metastatic Soft-tissue Sarcoma",[297,298,214,299,300],"Soft Tissue Sarcoma","Zanzalintinib","Nivolumab","Ipilimumab",{"date":216,"type":35},{"date":303,"type":35},"2026-01-05",{"date":305,"type":22},"2034-01-31",{"name":41,"class":42},{"id":308,"slug":4,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":105,"phases":316,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":335},"100585118","NCT06898203","Precision Imaging to Evaluate Kaposi Sarcoma","Precision Imaging to Evaluation Kaposi Sarcoma (PRIME-KS)","PRIME-KS","Inclusion Criteria - Aim 2 (Patients):\n\n* Adults age ≥18 years old\n* Histopathology-confirmed Kaposi Sarcoma\n* At least 3 skin lesions\n* Capable of informed consent\n* On treatment for Kaposi Sarcoma\n\nExclusion Criteria - Aim 2 (Patients):\n\n* Patients not initiating Kaposi Sarcoma treatment\n* Very ill patients requiring hospitalization\n\nInclusion Criteria - Aim 3 (Patients):\n\n* Adults age ≥18 years old\n* Histopathology-confirmed Kaposi Sarcoma\n* Capable of informed consent\n* Initiating treatment for Kaposi Sarcoma\n\nExclusion Criteria - Aim 3 (Patients):\n\n* Patients with Kaposi Sarcoma that participated in Aim 1 or Aim 2\n* Prior or ongoing Kaposi Sarcoma treatment",{"count":315,"type":22},300,[107],"AIMS 2 \\& 3:\n\nIn this study the investigators seek to formally compare reproducibility and accuracy of KS lesion size measurements between SkinScan3D and the current standard of care manual measurement method. The investigators will then test the SS3D device on 100 patients in a variety of real-world practice locations to determine whether the device will be usable, acceptable, appropriate, and feasible in routine care settings.",[319],"Kaposi Sarcoma",[321,319,322,323,324,325,326,327,328],"Global Oncology","Affordable Cancer Technologies","Cancer in People with HIV","Human Centered Design","Discrete Choice Experiment","Medical devices","Low-cost design","Global health",{"date":249,"type":35},{"date":331,"type":35},"2026-04-10",{"date":333,"type":22},"2029-11-30",{"name":41,"class":42},2,{"id":337,"slug":4,"hasResults":11,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":105,"phases":344,"briefSummary":345,"conditions":346,"keywords":350,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":362},"100615767","NCT07296887","CARE Tool Study Aim 3","Implement and Evaluate the CARE Tool in a Randomized Trial","Inclusion Criteria for Implementation champions:\n\n\\- Members of the cancer care team (e.g., physicians, nurses, research coordinators, financial navigators, social workers) that work with patients receiving treatment for gynecologic, lung, prostate, or colorectal cancer; or members of the billing team and employee of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n\nExclusion Criteria for Implementation champions:\n\n* Implementation champions are ineligible if they are non-employees of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n* Do not treat patients for gynecologic, prostate, lung, or colorectal cancer\n\nInclusion Criteria for Patients:\n\n* Age 18 and over\n* Primary or recurrent diagnosis of gynecologic, prostate, lung, or colorectal cancer in the last 12 months\n* Receiving cancer treatment from Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n* Self-reported ability to read and speak English\n\nExclusion Criteria for Patients:\n\n* Under the age of 18\n* Not diagnosed with gynecologic, prostate, lung, or colorectal cancer within the previous 12 months from recruitment\n* Not receiving care at Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital\n* Cannot give consent due to cognitive or emotional barriers",{"count":343,"type":22},430,[107],"This study is a multi-site randomized trial to study the implementation of the CARE Tool and evaluate the CARE Tool. The CARE Tool is a web-based tool that gives people information about cancer care costs, health insurance, and resources to help with costs. Overall, the study aims to help patients with cancer overcome barriers they face navigating insurance and accessing financial resources.",[347,236,348,349],"Gynecologic Cancer","Lung Cancer","Colorectal Cancer",[351,352,185,353,354],"Insurance","Insurance coverage","Cost of medical care","Financial toxicity","2026-06-27",{"date":249,"type":35},{"date":358,"type":35},"2026-04-08",{"date":360,"type":22},"2028-07-31",{"name":41,"class":42},3,{"id":364,"slug":4,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":43},"100505714","NCT05864976","Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning","Advancing Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning - a Prospective Study","Inclusion Criteria:\n\n* Must have a radiological diagnosis of a lesion in the brain with characteristics consistent with glioblastoma multiforme.\n* Must be planning to undergo a pre-operative MRI.\n* Must be at least 18 years old.\n* Must be able to understand and willing to sign an IRB approved written informed consent document.\n\nExclusion Criteria:\n\n* Contraindication to MRI.\n* Inability to have clinical follow-up (e.g., patient is out of town and will do follow-up elsewhere).",{"count":370,"type":22},100,"This study is investigating the use of a computer algorithm to analyze scans of the brain before surgery to predict how a person's tumor will respond to treatment.",[373],"Glioblastoma Multiforme","2026-06-26",{"date":216,"type":35},{"date":377,"type":35},"2023-12-06",{"date":379,"type":22},"2030-01-31",{"name":41,"class":42},{"id":382,"slug":4,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":51,"sex":17,"minAge":387,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":105,"phases":389,"briefSummary":390,"conditions":391,"keywords":394,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":398,"lastUpdatePostDateStruct":399,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":43},"100410825","NCT04629547","Sleep Trial to Prevent Alzheimer's Disease","SToP-AD","Inclusion Criteria:\n\n* Male or female.\n* Any race or ethnicity.\n* Participants must be age ≥65 years and able to sign informed consent.\n* Global Clinical Dementia Rating (CDR) 0.\n* Willing and able to undergo study procedures.\n\nExclusion Criteria:\n\n* History of reported symptoms suggestive of restless legs syndrome, narcolepsy or other central disorder of hypersomnolence, or parasomnia\n* STOP-Bang score \\>6 for participants without PAP\n* Untreated OSA with AHI ≥15 on home sleep test\n* Treated sleep apnea with PAP non-compliance\n\n  * PAP compliance is defined as \\>= 4 hours per night \\>70% of the nights\n* Plasma A-beta and tau test with a plasma p-tau 217% ≤ 1.19\n* Stroke.\n* Chronic kidney disease defined as patients with markers of kidney damage or eGFR of \\\u003C 45 ml\u002Fmin\u002F1.73m2.\n* Hepatic impairment defined as AST and\u002For ALT \\> 2x upper limit of normal (normal limits AST: 11-47 IU\u002FL, ALT: 6-53 IU\u002FL).\n* HIV\u002FAIDS.\n* History of substance abuse or alcohol abuse in the proceeding 6 months.\n* Regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime. Participants that agree to reduce alcohol consumption during the study may not be excluded.\n* History of presence of any clinically significant medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate.\n* Has any medical condition that, in the PI's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection\u002Fanalysis of the data. Potential medical conditions that will be exclusionary at the PI's discretion:\n\n  * Cardiovascular disease requiring medication except for controlled hypertension.\n  * Pulmonary disease.\n  * Type I diabetes.\n  * Neurologic or psychiatric disorder requiring medication.\n  * Tobacco use.\n  * Use of sedating medications.\n  * Use of medications that interact with suvorexant (if cannot be discontinued)\n  * Abnormal safety labs\n* History of current suicidal ideations.\n* Currently pregnant or breast-feeding.\n* In the opinion of the PI, the participant should be excluded due to an abnormal physical examination.\n* Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment.\n* Must not participate in another drug or device study prior to the end of this study participation.\n\nExclusion criteria for optional lumbar punctures\n\n-• Contraindication to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery).","65 Years",{"count":56,"type":22},[206],"The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.",[392,393],"Sleep","Alzheimer Disease",[395,396,397],"poor sleep","Amyloid-Beta","Insomnia","2026-06-25",{"date":216,"type":35},{"date":401,"type":35},"2022-05-25",{"date":403,"type":22},"2028-05",{"name":41,"class":42},{"id":406,"slug":4,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":105,"phases":413,"briefSummary":414,"conditions":415,"keywords":417,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":427,"locationsCount":362},"100615556","NCT07294144","Tofersen in Non-SOD1 ALS","A Study to Evaluate the Biological Effect of Tofersen in Adults With Amyotrophic Lateral Sclerosis Without Mutations in SOD1","Inclusion Criteria:\n\n* Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use PHI in accordance with national and local participant privacy regulations.\n* Aged 18 years or older at the time of informed consent.\n* Confirmed diagnosis of ALS.\n* Time since onset of weakness due to ALS ≤ 24 months at the time of the screening visit.\n* Prior confirmed genetic testing negative for SOD1 and FUS mutations. Participants with mutations in genes other than SOD1 and FUS may be enrolled at the discretion of the Site Investigator.\n* SVC ≥ 50% of predicted value as adjusted for sex, age, and height (from the sitting position).\n* Medically able to undergo the study procedures and to adhere to the visit schedule at the time of study entry, as determined by the Investigator.\n* All participants must agree to practice effective contraception during the study and be willing and able to continue contraception for 5 months after their last dose of study treatment.\n* If taking riluzole, participant must be on a stable dose for ≥ 30 days prior to Day 1 and expected to remain at that dose until the final study visit.\n* If taking edaravone, participant must have initiated edaravone ≥ 60 days (2 treatment cycles) prior to Day 1 and expected to remain at that dose until the final study visit, unless the Investigator determines that edaravone should be discontinued for medical reasons, in which case it may not be restarted during the study.\n\nExclusion Criteria:\n\n* Treatment with another investigational drug (including investigational drugs for ALS through compassionate use or expanded access programs), biological agent, or device within 1 month or 5 half-lives of study agent, whichever is longer. Specifically, no prior treatment with small interfering RNA, stem cell therapy, or gene therapy is allowed.\n* Current enrollment in any other interventional study.\n* History of drug abuse or alcoholism within ≤ 6 months of study enrollment that would limit participation in the study, as determined by the Investigator.\n* Presence of an untreated or inadequately treated active infection requiring systemic antiviral or antimicrobial therapy at any time during the screening period.\n* Ongoing medical condition (e.g., wasting or cachexia, severe anemia) that according to the Investigator would interfere with the conduct or assessments of the study.\n* History of confounding neuromuscular or neurological disorder that is expected to have a progressive (i.e., worsening) course during the study, and\u002For is expected to be associated with elevations in neurofilament, in the opinion of the Investigator.\n* Female participants who are pregnant or currently breastfeeding.\n* Significant cognitive impairment, clinical dementia, or unstable psychiatric illness, including psychosis, suicidal ideation, suicide attempt, or untreated major depression ≤ 90 days, as determined by the Investigator.\n* History of allergies to a broad range of anesthetics.\n* Tracheostomy.\n* Presence of risk for increased or uncontrolled bleeding and\u002For risk of bleeding that is not managed optimally could place a participant at an increased risk for intraoperative or postoperative bleeding. These could include, but are not limited to, anatomical factors at or near the LP site (e.g., vascular abnormalities, neoplasms, or other abnormalities) and underlying disorders of the coagulation cascade, platelet function, or platelet count (e.g., hemophilia, Von Willebrand's disease, liver disease).\n* Anticipated need, in the opinion of the Investigator, for administration of any antiplatelet or anticoagulant medication that cannot be safely held before and\u002For after an LP procedure according to local or institutional guidelines and\u002For Investigator determination.\n* Presence of an implanted shunt for the drainage of CSF or an implanted CNS catheter.\n* Clinically significant abnormalities in hematology or clinical chemistry parameters, as determined by the Investigator, which would render the participant unsuitable for enrollment.\n* Inability to comply with study requirements.\n* Other unspecified reasons that, in the opinion of the Investigator, make the participant unsuitable for enrollment.",{"count":412,"type":22},30,[206],"The goal of this clinical trial is to evaluate whether tofersen is safe and effective in adults with non-SOD1 ALS. Tofersen is currently approved by the U.S. Food and Drug Administration to treat SOD1-ALS. The main questions it aims to answer are:\n\n* Does tofersen lower the levels of neurofilament light chain (NfL) in the blood and CSF of adult participants with non-SOD1 ALS?\n* Is tofersen safe and tolerable for adult participants with non-SOD1 ALS?\n* Does tofersen affect other measurements such as clinical outcomes and quality-of-life measures in participants with non-SOD1 ALS?\n\nParticipants will :\n\n* Receive 100mg tofersen via lumbar puncture for 24 weeks. The doses are at the following time points: Weeks 0, 2, 4, 8, 12, 16, 20, and 24.\n* Complete 2 follow-up visits following the end of the dosing period at Weeks 28 and 32.\n* Complete a variety of questionnaires and outcome measurements such as strength and breathing testing.",[416],"ALS (Amyotrophic Lateral Sclerosis)",[418,419,420,421],"als","amyotrophic lateral sclerosis","tofersen","qalsody","2026-06-23",{"date":398,"type":35},{"date":425,"type":35},"2025-12-29",{"date":403,"type":22},{"name":41,"class":42},{"id":429,"slug":4,"hasResults":11,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":105,"phases":435,"briefSummary":436,"conditions":437,"keywords":440,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":43},"100644752","NCT07673380","Leveraging mHealth to Promote Opioid Use Recovery and Mental Health Among Residents of a Medium-Sized Midwestern City","Leveraging mHealth to Promote Recovery From Opioid Use Disorder and Commonly Occurring Mental Health Disorders Among Residents of a Medium-Sized Midwestern City","Inclusion Criteria:\n\n* Have a history of opioid and\u002For stimulant use\n* Identify as Black and\u002For African American\n* Seek treatment at local substance use treatment centers\n* Fluent in English\n* U.S. resident\n* 18 years of age or older at the time of data collection.\n\nExclusion Criteria:\n\n* Self-reported cognitive impairment that would limit ability to participate in research.",{"count":315,"type":22},[206],"The sequential trial compares recovery and mHealth engagement outcomes among Black participants who participated in the mHealth intervention uMAT-R or uMAT-R + enhanced community engagement. The mHealth intervention seeks to support people in various stages of recovery who are also seeking other forms of substance use treatment. Participants are recruited from community-based substance use treatment facilities and recovery services. Participants must be adults who have or are currently using opioids and\u002For stimulants.",[146,438,439],"Stimulant Use","Depression and Anxiety Symptoms",[441,442],"Digital health","Community engagement","2026-06-22",{"date":247,"type":35},{"date":446,"type":35},"2025-08-31",{"date":448,"type":22},"2027-02-28",{"name":41,"class":42},{"id":451,"slug":4,"hasResults":11,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":4,"eligibilityCriteria":455,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":456,"targetDuration":4,"studyType":105,"phases":457,"briefSummary":458,"conditions":459,"keywords":461,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":467,"completionDateStruct":468,"leadSponsor":470,"locationsCount":43},"100644338","NCT07662031","Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer","A Phase 2 Clinical Trial of Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed CRC.\n* Patient must have undergone resection of his\u002Fher primary tumor either as part of treatment for early stage disease with subsequent metastatic progression or due to a tumor related complication in the metastatic setting (e.g. bowel obstruction).\n* Measurable disease per RECIST 1.1.\n* Patient must have advanced or metastatic disease, and have progressed on one line of standard of care therapy in the advanced\u002Fmetastatic setting\n* At least 18 years of age.\n* ECOG performance status ≤ 2\n* Adequate bone marrow and organ function as defined below:\n\n  * Absolute neutrophil count ≥ 1.5 K\u002Fcumm\n  * Platelets ≥ 100 K\u002Fcumm\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN or ≤ 2.0 mg\u002FdL in presence of liver metastases\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3x IULN or ≤ 5x IULN in presence of liver metastases\n  * Creatinine clearance \\> 50 mL\u002Fmin by Cockcroft-Gault\n* The effects of Tovecimig and FOLFIRI on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 6 months after the last dose of Tovecimig or any component of FOLFIRI. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s\u002Fhe must inform her treating physician immediately.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Patients with MSI-H status.\n* Intact primary tumor that has not been resected.\n* More than one line of prior therapy for advanced or metastatic CRC.\n\n  \\*If FOLFIRI\u002FFOLFOXIRI was given in the first line, it must have been completed ≥ 6 months before study start date.\n* Surgery or major procedure, or systemic anticancer therapy within 4 weeks prior to C1D1.\n* Radiation therapy within 2 weeks prior to C1D1.\n* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.\n* Receipt of any other investigational agents within 4 weeks prior to C1D1, with exception of investigational imaging agents.\n* Patients with untreated brain metastases. Patients with treated brain metastases are allowed if post-treatment brain-imaging after CNS-directed therapy shows no evidence of progression.\n* Prior history of diseases\u002Fconditions that elevates the patient's risk of hemorrhage, such as a bleeding diatheses, history of prior bowel perforation, or clinically significant active bleeding (i.e. hemoptysis larger than a tablespoon within 3 weeks prior to C1D1).\n* Recent history of paracentesis (within 3 weeks prior to C1D1) or current indwelling catheter.\n* A history of hypersensitivity reactions attributed to compounds of similar chemical or biologic composition to Tovecimig (i.e. humanized\u002Fhuman monoclonal antibody drugs), FOFLIRI, or other agents used in the study.\n* Use of anticoagulants or thrombolytic agents for therapeutic (as opposed to prophylaxis) purpose within 10 days of C1D1.\n* Use of aspirin, other NSAIDs (i.e. naproxen, ibuprofen), or other antiplatelet drugs within 10 days of C1D1.\n* Uncontrolled intercurrent illness\u002Finfection requiring ongoing systemic antibiotics, antivirus drugs, or other uncontrolled active acute infectious diseases.\n* A history of CHF (NYHA class II or higher) with 5 years prior to C1D1, LVEF \\\u003C 50% on screening TTE\u002FMUGA, uncontrolled hypertension (defined as SBP\u002FDBP greater than 140\u002F90 despite best supportive care at any time during screening), pulmonary hypertension, myocardial infarction, uncontrolled arrhythmia, unstable angina, or any significant valvular disease.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of C1D1.\n* HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.\n* Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection.\n* History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection.",{"count":7,"type":22},[206],"This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).",[349,460],"Metastatic Colorectal Cancer",[462,463,464],"Tovecimig","Colorectal cancer","Microsatellite stable","2026-06-17",{"date":422,"type":35},{"date":280,"type":22},{"date":469,"type":22},"2032-08-31",{"name":41,"class":42},{"id":472,"slug":4,"hasResults":11,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":477,"targetDuration":4,"studyType":105,"phases":479,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":492,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":43},"100623155","NCT07392957","Safety and Efficacy of CTX-009 With or Without CTX-471 for Recurrent Glioblastoma","A Phase IB\u002FII Open-label Study of the Safety and Preliminary Efficacy of CTX-009 Administered Either as a Monotherapy or in Combination With CTX-471 in Patients With Recurrent Glioblastoma","Inclusion Criteria:\n\n* Histologically or radiographically confirmed recurrent CNS WHO grade 4 IDH wild-type glioma following standard of care treatment including radiation, chemotherapy, and\u002For tumor-treating fields. No more than 2 recurrences are allowed.\n* Patients may receive palliative treatment for recurrent disease prior to study enrollment with surgery or laser thermal ablation but must wait at least 4 weeks post-procedure to start study drug(s) and must have recovered from all procedure-related complications.\n* At least 18 years of age.\n* KPS performance status ≥ 60%\n* Adequate bone marrow and organ function as defined below:\n\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 75 K\u002Fcumm\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN, unless suspected or documented history of Gilbert's Syndrome, in which case ≤ 2.5 x IULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 2.5 x IULN\n  * Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault\n  * Urine Protein : Creatinine ratio (UPCR) \\\u003C 300 mg\u002Fg\n* QTcF \\\u003C 480 msec; in the setting of bundle branch block or other arrhythmia that makes QTcF unreliable, a JT interval \\\u003C 350 msec can be used as a substitute.\n* The effects of CTX-009 and CTX-471 on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 4 months after completion of study treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s\u002Fhe must inform her treating physician immediately.\n* Resolution, or stable control with medical management, of all prior anti-cancer therapy toxicities to ≤ grade 1 per NCI-CTCAE v5.0. If the patient has had major surgery, 4 weeks must have elapsed from the date of surgery and the first dose of study drug(s).\n* Stable or decreasing dose of corticosteroids and anti-seizure medications for 7 days prior to start of study drug(s). For Arm 2: a maximum of 2 mg daily dose of dexamethasone or equivalent at time of study drug(s) initiation is allowed.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Have progressed on prior anti-VEGF-A therapy (i.e., bevacizumab) or developed clinically significant adverse reaction to any anti-VEGF therapy (i.e., bevacizumab, regorafenib) which led to discontinuation of treatment. Prior treatment with low dose anti-VEGF therapy for management of symptomatic vasogenic edema or radiation necrosis is permitted as long as progression was not noted while receiving treatment with the anti-VEGF agent, and is not needed for continued control of symptoms. A 4-week washout from last dose of low-dose anti-VEGF therapy is required.\n* Prior systemic anti-cancer therapy including: investigational agents or immunotherapy within 4 weeks (can consider 2 week interval for agents with known 5 half-lives \\\u003C14 days following discussion with study PI); chemotherapy within 4 weeks (6 weeks for BCNU or CCNU); or targeted therapy within 2 weeks prior to treatment.\n\nNote: participants must have recovered from all clinically significant AEs due to previous therapies to ≤ grade 1 or baseline. This does not include AEs deemed not clinically significant by treating physician (i.e., alopecia). Participants with endocrine-related AEs ≤ grade 2 requiring treatment or hormone replacement are eligible if controlled (i.e., clinically asymptomatic) on stable dose of replacement therapy.\n\n* Use of aspirin, NSAIDs, or other antiplatelet agents within 7 days of study drug(s) initiation. Regular use (i.e., daily) of these agents should be avoided while on study treatment.\n* Use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes within 7 days of study drug(s) initiation. Prophylactic dosing of DOAC, such as apixaban or edoxaban, or LMWH for patency of venous access devices is allowed (preference is given to DOAC over LMWH).\n* History of intraparenchymal or subdural hemorrhage. History of hemorrhage-related or gastroenterological disease including active hemorrhage, hemorrhagic diathesis, coagulopathy, or tumor in great arteries. History of clinically significant gastroenterological disease, such as peptic ulcer, GI bleeding, GI or non-GI fistula, perforation, abdominal abscess, percutaneous drains, clinical symptoms and signs of GI obstruction, need for parenteral hydration or nutrition, or inflammatory bowel disease (IBD).\n* History of unprovoked high-risk thromboembolic events.\n* A history of the following cardiovascular diseases in the past 5 years (a case-by-case evaluation can be considered in consultation with the study PI):\n\n  * Congestive heart failure that corresponds to Class II or a higher class under NYHA classification or \\\u003C 50% of LVEF\n  * Uncontrolled hypertension (140\u002F90 mmHg despite best care including anti-hypertensive medications). White coat hypertension is not exclusionary.\n  * Hypertensive crisis or pre-existing hypertensive encephalopathy\n  * Pulmonary hypertension\n  * Myocardial infarction\n  * Uncontrolled arrhythmia\n  * Unstable angina\n* Significant vascular diseases (e.g., aortic aneurysm requiring surgery or recent peripheral artery thrombosis) within 6 months prior to study entry\n* For Arm 2: Prior treatment with other investigational immune-oncology therapies targeting CD137 (4-1BB).\n* For Arm 2: Systemic therapy with non-steroidal immunosuppressive agents within 7 days prior to first dose. Patients with a prior history of autoimmune disease not requiring immunosuppressive therapy may be eligible following discussion with the study PI. Topical, intranasal, intraocular, or inhaled corticosteroids and physiologic replacement for patients with adrenal insufficiency are allowed.\n* Prior solid organ or hematologic cell transplantation.\n* For Arm 2: Has received a live or live-attenuated vaccine within 30 days prior to the first dose. Note: administration of killed vaccines is allowed.\n* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to CTX-009 or CTX-471.\n* Active uncontrolled seizure disorder.\n* Active uncontrolled intercurrent illness including, but not limited to: infection, hypertension, open wound(s), or cardiac arrhythmia. Chronic illnesses controlled (i.e., clinically asymptomatic) with oral medications are allowed.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose for Arm 1 or 72 hours of first dose for Arm 2.\n* HIV-infected if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.\n* Evidence of chronic hepatitis B virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection.\n* History of hepatitis C virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection.",{"count":478,"type":22},54,[205,206],"This is a phase IB\u002FII, open-label study evaluating CTX-009 as monotherapy and in combination with CTX-471. The study evaluates the safety and efficacy of the monotherapy and the combination in patients with recurrent glioblastoma. The study tests the hypothesis that treatment with CTX-009 alone or in combination with CTX-471 will lead to enhanced tumor control and prolongation of overall survival of patients with recurrent glioblastoma.\n\nCTX-009 expands on existing anti-angiogenic therapies by ablating key compensatory and resistance mechanisms to bevacizumab, CTX-471 restores local immune reactivity through activation of costimulatory immune mediators. Combination of these two agents may further impair tumor proliferation through synergistic effects on the tumor microenvironment",[482],"Glioblastoma",[484,485,486,487,488,489,490,491],"VEGF","4-1BB","CD137","glioblastoma","immunotherapy","targeted therapy","CTX-009","CTX-471",{"date":443,"type":35},{"date":494,"type":35},"2026-06-16",{"date":496,"type":22},"2031-06-30",{"name":41,"class":42},{"id":499,"slug":4,"hasResults":11,"nctId":500,"briefTitle":501,"officialTitle":502,"acronym":503,"eligibilityCriteria":504,"healthyVolunteers":11,"sex":52,"minAge":18,"maxAge":4,"enrollmentInfo":505,"targetDuration":4,"studyType":105,"phases":507,"briefSummary":508,"conditions":509,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":514,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":335},"100600948","NCT07104123","Substance Use in Pregnant People - Optimizing Retention in Treatment","Substance Use in Pregnant People - Optimizing Retention in Treatment by Maximizing Opportunities for Management","SUPPORT-MOM","Inclusion Criteria:\n\nConfirmed viable intrauterine pregnancy at any gestational age, or within three years postpartum\n\nSUD as defined in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders or clinician documentation\n\nExclusion Criteria:\n\nDecline follow-up care at study site\n\nRequire immediate hospitalization for unstable medical or psychiatric conditions making them clinically unsuitable to participate in a research study",{"count":506,"type":22},40,[107],"Substance use during pregnancy is a leading cause of maternal morbidity and mortality in the United States, with 55-80% of postpartum patients disengaging from substance use disorder (SUD) treatment within one year of delivery. Structural and social determinants of health, including housing instability, transportation barriers, and limited childcare access, further exacerbate disparities in treatment retention.\n\nThis pilot study, conducted in two specialized prenatal care clinics, evaluates the feasibility and acceptability of two integrated strategies to promote sustained engagement in recovery-oriented services during the perinatal and postpartum periods. Aim 1 implements a standardized social needs screening and referral protocol to connect patients with community-based supports. Aim 2 pilots a contingency management intervention to incentivize recovery-supportive behaviors.\n\nFindings will inform the design of a larger multi-site randomized controlled trial to evaluate the impact of these interventions on treatment retention, overdose prevention, and maternal-infant health outcomes.",[510,511,512,513],"Substance Use Disorder (SUD)","Pregnancy","Postpartum","Contingency Management",{"date":443,"type":35},{"date":516,"type":35},"2026-02-02",{"date":518,"type":22},"2027-09",{"name":41,"class":42},{"id":521,"slug":4,"hasResults":11,"nctId":522,"briefTitle":523,"officialTitle":524,"acronym":4,"eligibilityCriteria":525,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":105,"phases":528,"briefSummary":529,"conditions":530,"keywords":535,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":43},"100556800","NCT06529822","Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease","Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease","Inclusion Criteria Cohort #1:\n\n* Age ≥ 18 years.\n* ECOG performance status ≤ 2 (Karnofsky ≥ 60%).\n* Histologically confirmed muscle-invasive bladder cancer (MIBC) or upper tract urothelial carcinoma (renal pelvis and\u002For ureter).\n* Patients with carcinomas showing mixed histologies are required to have a dominant transitional cell pattern.\n* Complete surgical resection of MIBC (R0) or upper tract urothelial carcinoma (renal pelvis and\u002For ureter). Tumor, nodes, metastases (TNM) classification (based on the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th ed.) at pathological examination of surgical resection specimen as follows: pT2-4aN0M0 or pT0-4aN+M0.\n* Patient must have fully recovered from surgical resection in the opinion of the treating MD.\n* ctDNA positive result as identified by Signatera.\n* Radiologic confirmation (by conventional imaging) of absence of residual disease and absence of metastasis.\n* Adequate bone marrow and organ function as defined below:\n\n  * WBC ≥ 1.5 K\u002Fcumm\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 50 K\u002Fcumm\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault\n* The effects of synthetic long peptide personalized cancer vaccines and Hiltonol on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 5 months after completion of study interventions. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s\u002Fhe must inform her treating physician immediately.\n* No concurrent investigational therapies outside of this protocol are allowed.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria Cohort #1:\n\n* Receiving any other investigational agents, or planning to receive other investigational agents as part of neoadjuvant therapy. Patients who have received perioperative neoadjuvant chemotherapy and immunotherapy are allowed.\n* Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.\n* A psychiatric illness or social situations that would limit compliance with study requirements as determined by the investigator from the medical history, physical exam, and\u002For medical record.\n* Prior or currently active autoimmune disease requiring management with immunosuppression. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. In the case of asthma or chronic obstructive pulmonary disease taking inhaled corticosteroids that does not require daily systemic corticosteroids is acceptable. Additionally, local acting steroids (topical, inhaled, or intraarticular) will be allowed. Patients on intermittent or short course steroids will be allow if the dose does not exceed 4 mg of dexamethasone (or equivalent) per day for \\> 7 consecutive days. Premedication for chemotherapy does not apply to this criterion and may be administered as per SOC practice. Any patients receiving steroids should be discussed with the PI to determine if eligible.\n* Known HIV-positive status.\n* History of positive test for Hepatitis B virus surface antigen (HBsAg) and\u002For positive Hepatitis C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia. For treatment enrollment the patient must have completed all prior cancer treatments \\> 28 days prior to vaccine administration with the exception of adjuvant SOC immunotherapy.\n* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial per discussion with the PI.\n* Currently receiving any other investigational agents.\n* Live vaccine administered within 30 days prior to enrollment.\n* Immunodeficiency, systemic steroid therapy, or any other immunosuppressive therapy within 30 days of enrollment.\n* Active autoimmune disease (excluding diabetes mellitus and\u002For vitiligo), solid organ or allogeneic bone marrow transplant, or other known contraindications to receiving immunotherapy.\n* Severe hypersensitivity (grade ≥ 3) to checkpoint inhibitors and\u002For any of its excipients.\n* Current pneumonitis, a history of (non-infectious) pneumonitis requiring steroids, or history of clinically significant interstitial lung disease.\n* Active tuberculosis test within 3 months prior to treatment initiation.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum\u002Furine pregnancy test within 7 days of study entry.\n\nInclusion Criteria Cohort #2:\n\n* Age ≥ 18 years.\n* ECOG performance status ≤ 2 (Karnofsky ≥ 60%)\n* Histologically confirmed gastroesophageal adenocarcinoma\n* Stage II or III gastroesophageal adenocarcinoma (GEC).\n* Complete surgical resection of GEC (R0). Full recovery from surgery and enrollment within 52 weeks following surgery with curative intent. Tumor, nodes, metastases (TNM) classification (based on the American Joint Committee on Cancer (AJCC) Cancer Staging Manual 8th ed.) at pathological examination of surgical resection specimen as follows:\n\n  * Esophageal and Esophagogastric junction adenocarcinoma T1 N1-3 M0 or T2-4 N0-2M0.\n  * Gastric adenocarcinoma T1-2 N1-3 M0 or T3-4 N0-3 M0.\n* Patient must have fully recovered from surgical resection in the opinion of the treating MD.\n* ctDNA positive result as identified by Signatera.\n* Radiologic confirmation (by conventional imaging) of absence of residual disease and absence of metastasis.\n* Adequate bone marrow and organ function as defined below:\n\n  * WBC ≥ 1.5 K\u002Fcumm\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 50 K\u002Fcumm\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault\n* The effects of synthetic long peptide personalized cancer vaccines and Hiltonol and on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 5 months after completion of study interventions. Should a woman become pregnant or suspect she is pregnant while participating in this study or should a man suspect he has fathered a child, s\u002Fhe must inform her treating physician immediately.\n* No concurrent investigational therapies outside of this protocol are allowed.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria Cohort #2:\n\n* Receiving any other investigational agents or planning to receive other investigational agents as part of neoadjuvant therapy. Patients who have received perioperative neoadjuvant chemotherapy and immunotherapy are allowed.\n* Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.\n* A psychiatric illness or social situations that would limit compliance with study requirements as determined by the investigator from the medical history, physical exam, and\u002For medical record.\n* Prior or currently active autoimmune disease requiring management with immunosuppression. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. In the case of asthma or chronic obstructive pulmonary disease taking inhaled corticosteroids that does not require daily systemic corticosteroids is acceptable. Additionally, local acting steroids (topical, inhaled, or intraarticular) will be allowed. Patients on intermittent or short course steroids will be allow if the dose does not exceed 4 mg of dexamethasone (or equivalent) per day for \\> 7 consecutive days. Premedication for chemotherapy does not apply to this criterion and may be administered as per SOC practice. Any patients receiving steroids should be discussed with the PI to determine if eligible.\n* Known HIV-positive status.\n* History of positive test for Hepatitis B virus surface antigen (HBsAg) and\u002For positive Hepatitis C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.\n* Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities \\> Grade 1) with the exception of alopecia. For treatment enrollment the patient must have completed all prior cancer treatments \\> 28 days prior to vaccine administration with the exception of adjuvant SOC immunotherapy.\n* Prior or concurrent malignancy whose natural history has the potential to interfere with the safety or efficacy assessment of the investigational regimen. Patients with prior or concurrent malignancy that does NOT meet that definition are eligible for this trial per discussion with the PI.\n* Currently receiving any other investigational agents.\n* Live vaccine administered within 30 days prior to enrollment.\n* Immunodeficiency, systemic steroid therapy, or any other immunosuppressive therapy within 30 days of enrollment.\n* Active autoimmune disease (excluding diabetes mellitus and\u002For vitiligo), solid organ or allogeneic bone marrow transplant, or other known contraindications to receiving immunotherapy.\n* Severe hypersensitivity (grade ≥ 3) to checkpoint inhibitors and\u002For any of its excipients.\n* Current pneumonitis, a history of (non-infectious) pneumonitis requiring steroids, or history of clinically significant interstitial lung disease.\n* Active tuberculosis test within 3 months prior to treatment initiation.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum\u002Furine pregnancy test within 14 days of study entry.\n\nInclusion Criteria Cohort #3:\n\n* Age ≥ 18 years.\n* ECOG performance status ≤ 1.\n* Histologically or cytologically confirmed diagnosis of Melanoma. Stage IIB\u002FC or IIIB-C (per AJCC 8th edition). Completed R0 resection within 36 months prior to enrollment and have fully recovered from surgery.\n* Planning to receive or have received adjuvant immunotherapy for 1 year.\n* Availability of a SignateraTM ctDNA report within 28 days prior to enrollment demonstrating ctDNA-positivity (MRD+). Note: Patients may be pre-screened prior to obtaining ctDNA results to facilitate assay design.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n* Radiologic confirmation (by conventional imaging) of absence of residual disease and absence of metastasis.\n* Adequate bone marrow and organ function as defined below:\n\n  * WBC ≥ 1.5 K\u002Fcumm\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 50 K\u002Fcumm\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria Cohort #3:\n\n* Receiving any other investigational agents or planning to receive other investigational agents in the neoadjuvant or adjuvant setting.\n* Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.\n* A psychiatric illness or social situation that would limit compliance with study requirements as determined by the investigator from the medical history, physical exam, and\u002For medical record.\n* Prior or currently active autoimmune disease requiring management with immunosuppression. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. In the case of asthma or chronic obstructive pulmonary disease, taking inhaled corticosteroids that do not require daily systemic corticosteroids is acceptable. Additionally, local acting steroids (topical, inhaled, or intraarticular) will be allowed. Patients on intermittent or short course steroids will be allowed if the dose does not exceed 4 mg of dexamethasone (or equivalent) per day for \\> 7 consecutive days. Systemic steroids must be discontinued at least 7 days prior to the first dose of SLP-01. Premedication for chemotherapy does not apply to this criterion and may be administered as per SOC practice. Any patients receiving steroids should be discussed with the PI to determine if they are eligible for this investigational treatment.\n* History of allogeneic stem cell transplant of solid organ transplant.\n* History of grade ≥3 immune-related adverse events with prior checkpoint inhibitors that, in the investigator's opinion, preclude further IO or vaccine therapy.\n* Untreated or unstable CNS metastases.\n* Known HIV-positive status.\n* History of positive test for Hepatitis B virus surface antigen (HBsAg) and\u002For positive Hepatitis C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum\u002Furine pregnancy test within 7 days of study entry.\n\nInclusion Criteria Cohort #4:\n\n* Age ≥ 18 years.\n* ECOG performance status ≤ 1.\n* Histological diagnosis of non-small cell lung carcinoma, stages II, IIIA or IIIB with complete R0 resection. Completed R0 resection within 9 months of surgery.\n* Planned to receive or have received adjuvant immunotherapy for 1 year.\n* Availability of a SignateraTM ctDNA report within 28 days prior to enrollment demonstrating ctDNA-positivity (MRD+). Note: Patients may be pre-screened prior to obtaining ctDNA results to facilitate assay design.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n* Radiologic confirmation (by conventional imaging) of absence of residual disease and absence of metastasis.\n* Adequate bone marrow and organ function as defined below:\n\n  * WBC ≥ 1.5 K\u002Fcumm\n  * Absolute neutrophil count ≥ 1.0 K\u002Fcumm\n  * Platelets ≥ 50 K\u002Fcumm\n  * Hemoglobin ≥ 8.0 g\u002FdL\n  * Total bilirubin ≤ 1.5 x IULN\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Creatinine clearance \\> 30 mL\u002Fmin by Cockcroft-Gault\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria Cohort #4:\n\n* Receiving any other investigational agents or planning to receive other investigational agents in the neoadjuvant or adjuvant setting.\n* Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty.\n* A psychiatric illness or social situation that would limit compliance with study requirements as determined by the investigator from the medical history, physical exam, and\u002For medical record.\n* Prior or currently active autoimmune disease requiring management with immunosuppression. This includes inflammatory bowel disease, ulcerative colitis, Crohn's disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia, immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, sarcoidosis, or other rheumatologic disease or any other medical condition or use of medication (e.g., corticosteroids) which might make it difficult for the patient to complete the full course of treatments or to generate an immune response to vaccines. In the case of asthma or chronic obstructive pulmonary disease, taking inhaled corticosteroids that do not require daily systemic corticosteroids is acceptable. Additionally, local acting steroids (topical, inhaled, or intraarticular) will be allowed. Patients on intermittent or short course steroids will be allowed if the dose does not exceed 4 mg of dexamethasone (or equivalent) per day for \\> 7 consecutive days. Systemic steroids must be discontinued at least 7 days prior to the first dose of SLP-01. Premedication for chemotherapy does not apply to this criterion and may be administered as per SOC practice. Any patients receiving steroids should be discussed with the PI to determine if they are eligible for this investigational treatment.\n* Known EGFR activating mutations (exon 19 deletion or L858R) or ALK, RET, or ROS1 gene rearrangements in subjects for whom adjuvant targeted therapy is planned.\n* History of allogeneic stem cell transplant or solid organ transplant.\n* History of grade ≥3 immune-related adverse events with prior checkpoint inhibitors that, in the investigator's opinion, preclude further IO or vaccine therapy.\n* Known HIV-positive status.\n* History of positive test for Hepatitis B virus surface antigen (HBsAg) and\u002For positive Hepatitis C antibody result with detectable hepatitis C virus (HCV) ribonucleic acid (RNA) indicating acute or chronic infection.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative serum\u002Furine pregnancy test within 7 days of study entry.",{"count":527,"type":22},64,[205],"This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.",[531,532,533,534],"Muscle-Invasive Bladder Carcinoma","Gastroesophageal Adenocarcinoma","Melanoma","Non-small Cell Lung Cancer",[536,537,214,538,532,539,533,540,212],"Personalized cancer vaccine","Solid tumor","Bladder cancer","GEC","NSCLC",{"date":542,"type":35},"2026-06-18",{"date":544,"type":35},"2025-03-20",{"date":546,"type":22},"2034-06-30",{"name":41,"class":42},{"id":549,"slug":4,"hasResults":11,"nctId":550,"briefTitle":551,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":105,"phases":556,"briefSummary":557,"conditions":558,"keywords":560,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":570,"completionDateStruct":572,"leadSponsor":573,"locationsCount":43},"100642527","NCT07660250","Vagus Nerve Stimulation for Myelopathy","Vagus Nerve Stimulation to Improve Post-operative Outcomes of Degenerative Cervical Myelopathy","Inclusion Criteria:\n\n* 18 years of age or older\n* Moderate or severe degenerative cervical myelopathy according to the mJOA\n* Decompression surgery planned\n\nExclusion Criteria:\n\n* • Pregnancy\n\n  * Electrically active implants (e.g. pacemaker)\n  * Known diagnosis of amyotrophic lateral sclerosis, multiple sclerosis, rheumatoid arthritis, concomitant thoracic and\u002For lumbar stenosis, spine tumor, HIV-related myelopathy\n  * Ongoing cancer therapy\n  * Ongoing use of immunomodulating or suppressive medication\n  * Sustained bradycardia with a heartrate \\\u003C50 beats per minute for \\> 5 minutes following admission.\n  * Prior cervical spine surgery",{"count":555,"type":22},36,[107],"The objective of this study is to generate preliminary data to establish the feasibility and effectiveness of transauricular vagus nerve stimulation (taVNS) to improve post-operative outcomes of moderate to severe degenerative cervical myelopathy (DCM)",[559],"Degenerative Cervical Myelopathy",[561,562,563,564,565,566,567],"degenerative cervical myelopathy","myelopathy","cervical myelopathy","degenerative myelopathy","vagus nerve","vagus nerve stimulation","ear stimulation","2026-06-15",{"date":443,"type":35},{"date":571,"type":35},"2026-04-14",{"date":403,"type":22},{"name":41,"class":42},{"id":575,"slug":4,"hasResults":11,"nctId":576,"briefTitle":577,"officialTitle":577,"acronym":4,"eligibilityCriteria":578,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":579,"targetDuration":4,"studyType":105,"phases":581,"briefSummary":582,"conditions":583,"keywords":587,"overallStatus":189,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":592,"startDateStruct":593,"completionDateStruct":594,"leadSponsor":596,"locationsCount":43},"100641329","NCT07659678","CCR2 PET Imaging Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Adult patient 18 years of age or older\n* Cohort 1: Newly diagnosed locally advanced T3-T4a, N0-3 and M0 squamous cell head and neck cancer scheduled to undergo standard of care surgery with or without neoadjuvant therapy OR Cohort 2: Suspected or biopsy proven recurrent\u002Fmetastatic squamous cell head and neck cancer scheduled to undergo first-line anti-PD1 therapy. HPV status does not need to be known and both HPV+ and HPV- subjects are eligible to enroll\n* Lesion size of at least 1.0 cm in longest dimension by conventional imaging.\n* Able to give informed consent\n* Not currently pregnant or nursing: Female subjects must be surgically sterile (has had a documented bilateral oophorectomy and\u002For documented hysterectomy), post- menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of Cu-DOTA-ECL1i is negative\n\nExclusion Criteria:\n\n* Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer present within the last 2 years\n* Unable to tolerate approximately 60 min (total time) of PET\u002FCT imaging",{"count":580,"type":22},90,[206],"This is a prospective study to evaluate the sensitivity and specificity of Cu-64 DOTA-ECL1i PET\u002FCT imaging to serve as a novel precision imaging tool for patients with head and neck squamous cell carcinoma (HNSCC).",[584,585,586],"Head and Neck Squamous Cell Carcinoma","Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent\u002FMetastatic (R\u002FM)","Head and Neck Squamous Cell Carcinoma HNSCC",[588,589,590,591],"Head and neck cancer","P16+ and P16-","PET","CCR2",{"date":443,"type":35},{"date":280,"type":22},{"date":595,"type":22},"2032-03-31",{"name":41,"class":42},{"id":598,"slug":4,"hasResults":11,"nctId":599,"briefTitle":600,"officialTitle":601,"acronym":4,"eligibilityCriteria":602,"healthyVolunteers":51,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":105,"phases":605,"briefSummary":606,"conditions":607,"keywords":615,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":617,"startDateStruct":618,"completionDateStruct":619,"leadSponsor":621,"locationsCount":43},"100564976","NCT06636175","64Cu-LLP2A for Imaging Hematologic Malignancies","Early Phase I Evaluation of 64Cu-LLP2A for Imaging Hematologic Malignancies Part B","Inclusion Criteria Healthy Volunteer:\n\n* Adult 18 years of age or older\n* Able to give informed consent.\n* Able to comprehend and willing to follow instructions for study procedures as called for by the protocol\n* Capable of lying still and supine within the PET\u002FCT scanner for up to 75 minutes.\n* No illicit drug use or other inhaled drug use (including pharmacologic agents and illicit drugs) within the past year per self-reporting mechanisms.\n* No history of claustrophobia or other condition that has previously or would interfere with completion of protocol specified imaging sessions.\n* Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and\u002For documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64Cu-LLP2A) is negative.\n\nInclusion Criteria Hematological Malignancy:\n\n* Clinical or pathologically defined MM or lymphoma including both newly diagnosed, relapsed or refractory disease:\n\n  * Multiple Myeloma defined in accordance with the International Myeloma Working Group criteria\n  * Low-grade lymphoma, including the following subtypes: follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma\u002Fchronic lymphocytic leukemia\n* Adult 18 years of age or older and able to provide informed consent\n* Capable of lying still and supine within the PET\u002FCT scanner for up to 75 minutes.\n* No history of claustrophobia or other condition that has previously or would interfere with completion of protocol specified imaging sessions\n* Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and\u002For documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64Cu-LLP2A) is negative\n* Patients participating in imaging or therapeutic trials with investigational agents are eligible to participate",{"count":604,"type":22},42,[264],"This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with negative imaging and suspected recurrence.",[608,609,610,611,612,613,614],"Multiple Myeloma","Low-Grade Lymphoma","Follicular Lymphoma","Marginal Zone Lymphoma","Lymphoplasmacytic Lymphoma","Small Lymphocytic Lymphoma","Chronic Lymphocytic Leukemia",[590,616],"Imaging",{"date":465,"type":35},{"date":544,"type":35},{"date":620,"type":22},"2027-03-31",{"name":41,"class":42},""]